NCT03602560已完成3 期
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 265
- 试验地点
- 156
- 主要终点
- Percentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at Month 3
研究概览
简要总结
A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)
The participants might enter the ongoing open-label safety study (NCT03301506) following this double-blind study.
详细描述
Primary:
- To evaluate the safety and effect on cholestasis of two seladelpar regimens (5 mg/day titrated to 10 mg/day and 10 mg/day) over 52 weeks of treatment compared to placebo
Key Secondary:
- To evaluate the effect of seladelpar on normalization of alkaline phosphatase (AP) levels
- To evaluate the effect of seladelpar on pruritus
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have given written informed consent (signed and dated) and any authorizations required by local law
- •18 to 75 years old (inclusive)
- •Male or female with a diagnosis of PBC, by at least two of the following criteria:
- •History of AP above ULN for at least six months
- •Positive anti-mitochondrial antibody (AMA) titers (>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay [ELISA]) or positive PBC-specific antinuclear antibodies
- •Documented liver biopsy result consistent with PBC
- •On a stable and recommended dose of UDCA for the past twelve months OR intolerant to UDCA (last dose of UDCA > 3 months prior to Screening)
- •AP ≥ 1.67 × ULN
- •Females of reproductive potential must use at least one barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose
排除标准
- •Previous exposure to seladelpar (MBX-8025)
- •A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer)
- •AST above 3 × ULN
- •ALT above 3 × ULN
- •Total bilirubin above 2.0 × ULN
- •Advanced PBC as defined by the Rotterdam criteria (albumin below LLN AND total bilirubin above 1 × ULN)
- •Creatine kinase (CK) above 1.0 × ULN
- •eGFR below 60 mL/min/1.73 m2 (calculated by MDRD formula)
- •International normalized ratio (INR) above 1.0 × ULN
- •Platelet count below 100 × 103/µL
- •Presence of clinically significant hepatic decompensation, including:
- •History of liver transplantation, current placement on liver transplantation list, or current MELD score ≥ 15
- •Complications of portal hypertension, including known esophageal varices, history of variceal bleeds or related interventions (e.g., transjugular intrahepatic portosystemic shunt placement), relevant ascites, hepatic encephalopathy
- •Cirrhosis with complications, including history or presence of spontaneous bacterial peritonitis
- •Other chronic liver diseases:
- •Current features of auto-immune hepatitis as determined by the investigator based on immunoserology, liver biochemistry and histology
- •Primary sclerosing cholangitis determined by presence of diagnostic cholangiographic findings
- •History or clinical evidence of alcoholic liver disease
- •History or clinical evidence of alpha-1-antitrypsin deficiency
- •Biopsy confirmed nonalcoholic steatohepatitis
- •History or evidence of Gilbert' Syndrome with elevated total bilirubin
- •History or evidence of hemochromatosis
- •Hepatitis B defined as presence of hepatitis B surface antigen (HBsAg)
- •Hepatitis C defined as presence of HCV RNA
- •Known history of HIV
- •Evidence of significant alcohol consumption
- •Evidence of drug abuse
- •Subjects with inadequate response to obeticholic acid (OCA) or intolerance to OCA: OCA must be discontinued 30 days prior to Screening
- •Use of colchicine, methotrexate, azathioprine, or long-term systemic corticosteroids (> 2 weeks) within two months prior to Screening
- •Use of fibrates within 30 days prior to Screening
- •Use of simvastatin within 7 days prior to Screening
- •Use of an experimental or unapproved treatment for PBC within 30 days prior to Screening
- •Use of experimental or unapproved immunosuppressant within 30 days prior to Screening
- •Treatment with any other investigational therapy or device within 30 days or within five half-lives, whatever is longer, prior to Screening
- •For females, pregnancy or breast-feeding
- •Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the investigator
研究组 & 干预措施
Seladelpar 5-10 mg
Experimental
干预措施: seladelpar 5-10 mg (Drug)
Seladelpar 10 mg
Experimental
干预措施: seladelpar 10 mg (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Percentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at Month 3
时间窗: Month 3
Percentage of Participants with Response to Composite Endpoint of ALP \<1.67 × Upper Limit of Normal \[ULN\], ≥15% reduction in ALP, and total bilirubin ≤ ULN) at Month 3. The mITT analysis set included all randomized subjects who received at least one study drug dose. The primary endpoint was analyzed using Cochran-Mantel-Haenszel (CMH) test adjusted for both randomization stratification variables (ALP level: \<350 U/L and 2:350 U/L; pruritus NRS: \<4 and 2:4). The CMH tests were performed for the comparison of 10 mg versus placebo and 5 mg/10 mg versus placebo separately.
次要结局
- Change From Baseline in Pruritus NRS for Subjects With Baseline NRS ≥4 at Month 3(Month 3)
- Percentage of Participants With Response Defined by Normalized Alkaline Phosphatase Levels at Month 3(Month 3)
研究者
研究点 (156)
Loading locations...
相似试验
招募中
3 期
ICP-332 in Subjects With Moderate to Severe Atopic DermatitisAtopic DermatitisNCT06775860Beijing InnoCare Pharma Tech Co., Ltd.552
已完成
3 期
Study of AA4500 in the Treatment of Peyronie's DiseasePeyronie's DiseaseNCT01221597Endo Pharmaceuticals418
已完成
3 期
Study of AA4500 in the Treatment of Peyronie's DiseasePeyronie's DiseaseNCT01221623Endo Pharmaceuticals418
终止
3 期
Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic StrokeAcute Ischemic StrokeNCT01098981Cerevast Therapeutics, Inc.675
已完成
3 期
A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee PainOsteoarthritis, KneeNCT03429049Centrexion Therapeutics332